New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
16:21 EDTAMGN, ABCAmgen gets court approval in previously announced $762M settlement with FDA
U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by Amgen (AMGN) for illegally introducing a misbranded drug into interstate commerce, and approved Amgen’s global settlement with the United States in which Amgen agreed to pay $762M to resolve criminal and civil liability arising from its sale and promotion of certain drugs. Under the terms of the criminal plea agreement, Amgen will pay a criminal fine of $136M and criminal forfeiture in the amount of $14M. As part of the civil settlement, Amgen has agreed to pay $612M, of which $587.2M is to the United States and $24.8M to the states, to resolve claims that it caused false claims to be submitted to Medicare, Medicaid and other government insurance programs. In a separate civil settlement, International Nephrology Network, renamed Integrated Nephrology Network, a subsidiary of AmerisourceBergen Corporation (ABC), has also agreed to pay $15M to resolve civil liability arising from its role in the marketing of Aranesp. Reference Link
News For AMGN;ABC From The Last 14 Days
Check below for free stories on AMGN;ABC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:21 EDTAMGNAmgen submitts MAA to EMA for evolocumab
Subscribe for More Information
08:20 EDTAMGNAmgen submits application to EMA for talimogene laherparepvec
Subscribe for More Information
08:01 EDTAMGNAmgen price target raised to $153 from $140 at Leerink
Subscribe for More Information
August 31, 2014
12:50 EDTAMGNEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 28, 2014
09:18 EDTAMGNAmgen anounces Evolocumab YUKAWA-2 study meets co-primary endpoints
Subscribe for More Information
09:04 EDTAMGNAmgen submits evolocumab BLA to FDA
Subscribe for More Information
August 27, 2014
09:20 EDTAMGNFDA grants Amgen priority review designation for ivabradine
Amgen announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure. Ivabradine is an oral drug that inhibits the If current in the sinoatrial node, the body's cardiac pacemaker. The New Drug Application is based on global clinical trial data from the Phase 3 SHIFT, or Systolic Heart failure treatment with the If inhibitor ivabradine Trial), study. The SHIFT study compared ivabradine to placebo on top of standard-of-care therapies, including beta-blockers, in more than 6,500 patients in sinus rhythm with reduced left ventricular function and heart rate greater than 70 beats per minute.
August 26, 2014
11:21 EDTAMGNAmgen added to short term buy list at Deutsche Bank
Subscribe for More Information
August 25, 2014
16:17 EDTAMGNWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
August 19, 2014
05:11 EDTAMGNGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use